This is a working overview of REV-ERB, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-01-20 and is reviewed periodically as new material appears.
SR9009 is often grouped with compounds studied for circadian and metabolic regulation rather than with classical anabolic steroids. Its interactions with nuclear receptors differ from those of androgen receptor ligands, and its proposed mechanisms involve transcriptional control rather than direct hormone signaling. Some sources classify it as a metabolic modulator because of observed effects on energy utilization. The distinction matters for regulation and for interpreting research results across different compound classes.
SR9009 is a synthetic small molecule developed as a REV-ERB agonist. It binds to REV-ERBα and REV-ERBβ, nuclear receptors that help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, the compound alters lipid and glucose handling and influences skeletal muscle oxidative capacity. Its exact effects in humans remain largely uncharacterized because controlled clinical trials have not been reported. The molecule is frequently described in preclinical literature as a metabolic modulator.
Research interest in SR9009 grew from studies showing improved running endurance in mice after short treatment periods. Those experiments linked the compound to increased mitochondrial content and fatty acid oxidation in muscle, but the findings come from animal models and specific dosing schedules. Independent replication has been limited, and the pathways connecting REV-ERB activation to exercise performance are still being mapped. Whether similar responses occur in humans is an open question.
Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ, also called NR1D1 and NR1D2. These receptors help regulate circadian rhythms and metabolic gene programs. The compound was developed for laboratory research, not as an approved therapeutic. Its identity is distinct from steroid hormones and selective androgen receptor modulators. Scientific interest centers on how REV-ERB activation changes gene expression in cells and animal models.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C20H24ClN3O4S | Reported for the free base |
| Molecular weight | 437.9 g/mol | Calculated from the formula |
| Primary target | REV-ERBα and REV-ERBβ | Nuclear receptors involved in circadian regulation |
| Solubility | Soluble in DMSO and ethanol | Poorly soluble in water |
| Typical storage | -20 °C, desiccated | Protect from light and moisture |
Research interest in SR9009 grew from studies of circadian biology and metabolic disease. Preclinical reports describe effects on exercise capacity, muscle metabolism, and blood lipid levels in rodents, but these findings come from controlled laboratory settings. The compound has low oral bioavailability in animals, which limits systemic exposure after swallowing. Investigators often use injected routes in experiments to achieve measurable plasma concentrations. Human clinical data are sparse, no approved therapeutic product exists, and whether animal effects translate to humans remains an open question.
Regulatory and sporting contexts treat SR9009 as a prohibited substance in many elite competitions. Its presence on banned lists reflects concerns about performance enhancement and unknown long-term safety. Analytical chemists have developed methods to detect the parent compound and its metabolites in urine and blood. Literature discussions distinguish between in vitro potency, animal pharmacology, and anecdotal human reports. The latter are difficult to verify because products sold online may lack purity or contain different compounds.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms, lipid metabolism, and inflammatory gene expression. In cell and animal experiments, SR9009 alters transcription of clock-controlled genes and metabolic pathways. The compound is not a hormone and does not resemble classical steroid structures. Its activity depends on binding to the ligand-binding domain of REV-ERB, where it can modify corepressor recruitment.
Most published work on SR9009 consists of preclinical studies. It is widely sold as a research chemical, a category that does not imply safety, efficacy, or pharmaceutical-grade quality. Sports anti-doping organizations have listed SR9009 as a prohibited substance, and its presence in an athlete sample can lead to sanctions. Legal status differs by country; in several jurisdictions it is not approved for human consumption and may be treated as an unapproved new drug.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not a steroid, peptide, or natural hormone. In scientific literature, it appears under the code SR9009 and in non-scientific contexts as Stenabolic. The compound was identified through chemical screening efforts aimed at targeting circadian clock components. Its status remains investigational, and no regulatory agency has approved it as a human medicine.
The formation of the peptide bond consumes energy, which, in organisms, is derived from ATP. Peptides and proteins are chains of amino acids held together by peptide bonds (and sometimes by a few isopeptide bonds). Organisms use enzymes to produce nonribosomal peptides, and ribosomes to produce proteins via reactions that differ in details from dehydration synthesis. Some peptides, like alpha-amanitin, are called ribosomal peptides as they are made by ribosomes, but many are nonribosomal peptides as they are synthesized by specialized enzymes rather than ribosomes. For example, the tripeptide glutathione is synthesized in two steps from free amino acids, by two enzymes: glutamate–cysteine ligase (forms an isopeptide bond, which is not a peptide bond) and glutathione synthetase (forms a peptide bond).
The most abundant transdermal drug administration route currently is via hypodermic needles, transdermal patches, and topical creams. However, these routes have limited therapeutic effects because stratum corneum serves as a barrier that reduces the entry of drug molecules into the systemic circulation and target tissues. The invention of MNs have retained the benefits of both hypodermic needles and transdermal patches while minimizing their cons. Compared to hypodermic needles, MNs provide a pain-free administration. MNs are able to penetrate through the epidermis, but not any deeper to compress on nerve-ends to produce pain responses. The superficial penetration also lessens the infection risk. Compared to transdermal patches, MNs are proven to be effective in producing micropores on the epidermis. The micropores facilitate the absorption of large molecules, like calcein and insulin, by 4 times via in-vitro skin models. In addition, MNs' direct drug delivery to systemic circulation avoided the first-pass effect in the liver. Significantly increasing the drug bioavailability, and the fast absorption into the systemic circulation also allowed a fast onset of action. Therefore, MNs could benefit diabetes treatment as common oral delivery would lead to a significant loss of insulin from degradation in the liver (first-pass effect) and insulin molecules are too large to be absorbed using common transdermal patches.
== Tissue damaged by inflammation == After inflammation has damaged tissue (when combatting bacterial infection for example) and pro-inflammatory eicosanoids have completed their function, healing proceeds in 4 phases.
=== Reemergence === The use of animal glue, as well as some other types of glues, largely vanished in Europe after the decline of the Western Roman Empire until the 16th to 18th centuries, when wooden furniture started to surge as a major craft. During the Middle Ages, fish glue remained a source for painting and illuminating manuscripts. Since the 16th century, hide glue has been used in the construction of violins. Amerindians used hoof glue primarily as a binder and as a water-resistant coating by boiling it down from leftover animal parts and applying it to exposed surfaces. They occasionally used hide glue as paint to achieve patterns after applying pigments and tanning to hides. Hoof glue would be used for purposes aside from hides, such as as a hair preservative. The Assiniboine preferred longer hair, so they would plaster the strands with a mixture of red earth and hoof glue. It was also used to bind feathers and equipment together.
=== Marrow === Bone marrow, also known as myeloid tissue in red bone marrow, can be found in almost any bone that holds cancellous tissue. In newborns, all such bones are filled exclusively with red marrow or hematopoietic marrow, but as the child ages the hematopoietic fraction decreases in quantity and the fatty/ yellow fraction called marrow adipose tissue (MAT) increases in quantity. In adults, red marrow is mostly found in the bone marrow of the femur, the ribs, the vertebrae and pelvic bones.
Sources: en.wikipedia.org
=== Detecting mechanical damage to connective tissue === Collagen offers mechanical strength in load bearing tissues in the body such as tendons, ligaments, and bone. As forces are applied to these tissues, the collagen triple helix can be damaged and unwind, and CHPs allow for molecular level detection of mechanical damage in such connective tissues.
During his lifetime, Paracelsus was viewed as an adventurer who challenged the theories and mercenary motives of contemporary medicine with dangerous chemical therapies, but his therapies marked a turning point in Western medicine. In the 1660s, laudanum was recommended for pain, sleeplessness, and diarrhea by Thomas Sydenham, the renowned "father of English medicine" or "English Hippocrates", to whom is attributed the quote "Among the remedies which it has pleased Almighty God to give to man to relieve his sufferings, none is so universal and so efficacious as opium." Use of opium as a cure-all was reflected in the formulation of mithridatium described in the 1728 Chambers Cyclopedia, which included true opium in the mixture. Eventually, laudanum became readily available and extensively used by the 18th century in Europe, especially England. Compared to other chemicals available to 18th century regular physicians, opium was a benign alternative to arsenic, mercury, or emetics, and it was remarkably successful in alleviating a wide range of ailments. Due to the constipation often produced by the consumption of opium, it was one of the most effective treatments for cholera, dysentery, and diarrhea. As a cough suppressant, opium was used to treat bronchitis, tuberculosis, and other respiratory illnesses. Opium was additionally prescribed for rheumatism and insomnia. Medical textbooks even recommended its use by people in good health, to "optimize the internal equilibrium of the human body". During the 18th century, opium was found to be a good remedy for nervous disorders.
DMG-PEG 2000 is a synthetic lipid formed by the PEGylation of myristoyl diglyceride. It is used to manufacture lipid nanoparticles that are used in mRNA vaccines, and in particular forms part of the drug delivery system for the Moderna COVID-19 vaccine.
Black kōji produces citric acid during fermentation, which inhibits the growth of unwanted microorganisms. It is typically used for the production of awamori. There are three Aspergillus species that are used as black kōji:
Sources: en.wikipedia.org
Studies suggest that light pollution desynchronizes spawning in some coral species. In areas such as the Red Sea, as many as 10 out of 50 species may be showing spawning asynchrony, compared to 30 years ago. The establishment of new corals in the area has decreased and in some cases ceased. The area was previously considered a refuge for corals because mass bleaching events due to climate change had not been observed there. Coral restoration techniques for coral reef management are being developed to increase fertilization rates, larval development, and settlement of new corals.
Stringing is perhaps the most crucial of these effects, and is often seen on adhesive tapes. Stringing occurs when a separation of two surfaces is beginning and molecules at the interface bridge out across the gap, rather than cracking like the interface itself. The most significant consequence of this effect is the restraint of the crack. By providing the otherwise brittle interfacial bonds with some flexibility, the molecules that are stringing across the gap can stop the crack from propagating. Another way to understand this phenomenon is by comparing it to the stress concentration at the point of failure mentioned earlier. Since the stress is now spread out over some area, the stress at any given point has less of a chance of overwhelming the total adhesive force between the surfaces. If failure does occur at an interface containing a viscoelastic adhesive agent, and a crack does propagate, it happens by a gradual process called "fingering", rather than a rapid, brittle fracture. Stringing can apply to both the diffusive bonding regime and the chemical bonding regime. The strings of molecules bridging across the gap would either be the molecules that had earlier diffused across the interface or the viscoelastic adhesive, provided that there was a significant volume of it at the interface.
Stanton, along with 33 other Essendon players, was found guilty of using a banned performance-enhancing substance, thymosin beta-4, as part of Essendon's sports supplements program during the 2012 season. He and his team-mates were initially found not guilty in March 2015 by the AFL Anti-Doping Tribunal, but a guilty verdict was returned in January 2016 after an appeal by the World Anti-Doping Agency. He was suspended for two years which, with backdating, ended in November 2016; as a result, he served approximately fourteen months of his suspension and missed the entire 2016 AFL season. On 10 August 2016 Stanton re-committed to the Bombers on a one-year deal. Early in the 2017 season, Stanton played his 250th AFL game against the Brisbane Lions at the Gabba. On 24 August 2017, Stanton announced that he would retire at the end of the 2017 season.
=== TruB === The TruB family only contains PUS 4 located in the mitochondrion and nucleus. PUS 4 modification is heavily conserved located in the U55 in the elbow of the tRNA. The human form of PUS 4 is actually missing a binding domain called PUA or pseudouridine synthase and archaeosine trans-glycosylase. PUS 4 has a sequence specificity for T-loop part of the tRNA. Preliminary data of PUS4 modifying mRNA, but more research is needed to confirm. Also binds to a specific Brome Mosaic Virus, which is a plant-infecting RNA virus.
In March 1946, the government of Kimon Georgiev was reorganized—two ministries were added, the number of sub-chairmen was reduced, and there were personnel changes and changes in the proportions of the coalition parties. This was on the orders of Joseph Stalin, who criticised the Bulgarian communists for the slow imposition of the totalitarian regime in the country. He demanded the strengthening of the presence of the BPC and BZNS in the cabinet, the removal of the foreign minister Petko Staynov and a purge of the foreign ministry staff, and the replacement of the finance minister Stancho Cholakov. Despite the pressure against Zveno, Georgiev himself retained the confidence of Stalin and Georgi Dimitrov and remained at the head of the cabinet. Apart from being prime minister, he remained a minister without portfolio. On Joseph Stalin's direct instructions to Georgi Dimitrov, a purge in the army began in the summer of 1946, accompanied by public show trials against alleged officer organizations - "Tsar Krum", "Neutral Officer" and others, as well as opposition leaders such as G. M. Dimitrov and Krustyo Pastukhov. These were coordinated with the parallel mounted trial in Yugoslavia against Draža Mihailović, during which Mihailović's links with Bulgarian public figures such as G. М. Dimitrov, Asen Stamboliyski and the war minister Damyan Velchev. In this setting, Kimon Georgiev publicly spoke out in support of the Military Union and personally of Damyan Velchev, whom he called his "closest and most inseparable personal friend, political associate and comrade in the cabinet".
Sources: en.wikipedia.org
It is a synthetic REV-ERB agonist used mainly in preclinical research. It is not an approved medicine for human use.
It binds to REV-ERBα and REV-ERBβ, nuclear receptors involved in circadian and metabolic gene regulation. This can alter transcription of genes related to lipid and glucose metabolism in experimental models.
No controlled human trials have established that effect. Endurance findings come primarily from rodent studies, and human responses remain unknown.
SR9009 is a synthetic research compound that activates the REV-ERBα and REV-ERBβ nuclear receptors. It is not an approved drug and has no established human therapeutic use. Most published biological data come from cell and rodent studies.